In contrast, PDGFRA mutant and SDH-d GISTs may exhibit a more indolent clinical course (7); however, the majority of these GIST subtypes demonstrate little or no response to IM (8, 9) or other approved therapies. The gene discussed is PDGFRA; the disease is gastrointestinal stromal tumor.